We would love to hear your thoughts about our site and services, please take our survey here.
Regeneron launches five-year $500m biotech fund
1 HOUR AGO
Biopharma giant commits $100m annually to Regeneron Ventures as it seeks to ‘fuel promising biotech innovation.’
Yesterday, as we revealed 2023 was another tough year for longevity investment, biotech heavyweight Regeneron quietly announced the formation of Regeneron Ventures, a new $500 million venture capital fund. As the fund’s exclusive limited partner, Regeneron has pledged $100 million annually over the next five years to invest in promising life sciences companies.
While the new fund’s investment mandate is broadly health focused, Regeneron Ventures says its interest is “skewed towards biotechnology, devices, tools, and enabling technologies.” The fund says that investment decisions will be guided by the quality of the science, people, and data, prioritizing “breakthrough innovation” despite the inherent risks and uncertainties. All of which should resonate well with founders in the longevity sector, offering a potential new source of funding for biotech startups targeting aging and age-related diseases.
htTps://longevity.technology/news/regeneron-launches-five-year-500m-biotech-fund/amp/
SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
Epigenetic mechanism of action offers a promising new approach to tackling MDD
April 16, 2024 08:00 AM Eastern Daylight Time
MORRISVILLE, N.C.--(BUSINESS WIRE)-
-Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
htTps://www.businesswire.com/news/home/20240416487796/en/Arrivo-Bio-Initiates-Large-Phase-2b-Clinical-Trial-in-Major-Depressive-Disorder-with-Novel-SIRT6-Activator
Key highlights of the Founders Longevity Forum:
Exclusive event – The Founders Longevity Forum will host a minimum of 120 approved guests, including high-caliber investors, family offices, longevity founders and VIPs.
Comprehensive program – guests will enjoy a half-day of content, a welcome reception, a full-day program and automatic registration for London Tech Week.
Global reach – following the London event, the Founders Longevity Forum will travel to Abu Dhabi and San Francisco.
Longevity takes center stage – The Longevity Village at London Tech Week will elevate this dynamic industry, showcasing the companies applying new technologies to extend human healthspan.
htTtps://longevity.technology/news/founders-forum-and-longevity-technology-join-forces-to-accelerate-longevity-investment/
10th - 11th June 2024 - Organised by Longeity Technology who hold 3%. Gla ;-)
New international event program launches to bring longevity entrepreneurs and investors together.
Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.
The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.
Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.
“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”
Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.
The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.
“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.
“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”
“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.
“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”
Major Shareholders
ERIC LEIRE 124,000,000 35.5%
PREMIER MITON 32,000,000 9.2%
ARIAN BEESTON 17,475,000 5.0%
JONATHAN MARK SWANN 16,874,000 4.8%
SAMANTHA BAUER 14,500,000 4.1%
LONGEVITY TECH FUND 10,499,998 3.0%
SARAH BEESTON 10,000,000 2.9%
Very impressive, this is going to bounce big very soon. Gl :-)
Eric's £50k share subscription declared along with another 1.8% for Jonathan Swan who declared his 3% back in March. The smart Money is accumulating. Gla :-)
It's going to big...On and UP!!! Gla :-)
Cheers Porter, an excellent and informative interview and very encouraging on prospects and potential going forward. Exciting times ahead. Gl :-)
Great find Northeast and exciting news for Genflow. Gl :-)
First in human proof-of-concept Phase I/ II Trial in NASH
NASH or Non-Alcoholic Steatohepatitis is a liver disease with a significant unmet medical need. Effecting an estimated 35 million people worldwide, it is the most chronic liver condition in the West and patient numbers are growing rapidly. It is the leading cause of liver transplants due to the lack of approved therapies with the market for NASH therapy expected to reach $27.2B by 2029.
Recent pre-clinical programs have highlighted the adipogenic, anti-fibrotic, and anti-tumoral effects of GF-1002 positioning it as a promising treatment candidate for NASH.
By targeting NASH, Genflow Biosciences stands to benefit from a clear regulatory pathway that could lead to accelerated development and the potential for conditional fast-track approval.
It's all good and now look forward to a flow if positive news. Gla ;-)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,558 followers
7h
The first #NASH treatment is FDA approved! Despite its growing rates, the disease went largely understudied for decades - until now. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) and its peers are developing life saving medicine to change the lives of millions.
Read more: htTps://loom.ly/fYAsZzA
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
PUBLISHED TUE, MAR 19 2024
In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals' drug "Rezdiffra," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.
The agency's approval is also a big deal because it means Madrigal has succeeded in an area where several other drugmakers have failed – or are still trying to crack.
That gives Madrigal an edge in a market that could be huge: The MASH industry could be worth nearly $26 billion by 2032 across the U.S., France, Germany, Italy, Spain, the U.K. and Japan, according to an estimate from data analytics firm GlobalData.
Madrigal's drug is setting the bar for efficacy and safety for MASH treatment, while also opening the door for medicines still in development.
There's one important detail in the approval that could bode well for the entire MASH space: The FDA isn't requiring patients to get a liver biopsy to determine their eligibility for Madrigal's drug.
That refers to a procedure in which a doctor removes a small piece of liver tissue from a patient so they can examine it under a microscope for signs of damage or disease.
"The absence of liver biopsy requirement in Rezdiffra's label should buoy biotech stocks" of companies developing MASH treatments and "potentially accelerate and broaden patient access," William Blair analyst Andy Hsieh wrote in a note on Friday.
htTps://www.cnbc.com/2024/03/19/healthy-returns-first-nash-liver-disease-drug-is-here-more-coming.html
March 2024 Company Presentation
hTtps://genflowbio.com/wp-content/uploads/2024/03/GenflowBio_Presentation_3-6-24.pdf
That's my plan......On and UP!!! Gla ;-)
Lol, you've got a few more than me Northeast, but i'll be closing the gap tomorrow if all goes to plan. The current rockbottom low sp could be the bargain of the century in the not too distant , with multiple potential opportunities /scenarios to propel Genflow’s value skywards. Gl :-)
Plenty of buying today Northeast, but hopefully no news just yet as I'm planning to buy a few myself tomorrow, with funds incoming. Gl :-)
Yes indeed Northeast, no doubt Madrigal will want to protect/dominate the Nash space by acquisition , as well as other Major's currently involved in Nash R & D...... Exciting times ahead. Gl ;-)
Other biopharma players including Pfizer, Bristol Myers Squibb and Genfit have all tried to get into the NASH field as well. Madrigal’s offering, meanwhile, was the first to meet the goals of both MASH resolution and fibrosis improvement in a phase 3 study.
The company is pricing Rezdiffra at a wholesale acquisition cost of $47,400 before discounts. Analysts at Evercore ISI have previously pegged peak global sales at $5.5 billion, and the analyst team expects the drug to generate about $2.6 billion in 2030.
Crucially, the FDA’s approval comes without the requirement of a liver biopsy to determine patient eligibility. That was a major point of contention among investors ahead of the approval, as the invasive procedure would have constrained wide access to the med.
hTtps://www.fiercepharma.com/pharma/after-monumental-mash-nod-its-rezdiffra-madrigal-plots-600m-stock-sale-support-upcoming